Given Imaging M2A Cleared As First-Line Small Bowel Disorder Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
FDA's expanded clearance of Given Imaging's M2A camera pill allows the firm to compete directly with diagnostic procedures such as small bowel follow-through, push enteroscopy, intra-operative enteroscopy, CT and enteroclysis
You may also be interested in...
Given Imaging Targeting M2A Reimbursement Beyond Obscure Bleeding
A BlueCross BlueShield TEC assessment supporting capsule endoscopy for Crohn's disease diagnosis furthers Given Imaging's efforts to obtain coverage for indications beyond obscure bleeding
Given Imaging Targeting M2A Reimbursement Beyond Obscure Bleeding
A BlueCross BlueShield TEC assessment supporting capsule endoscopy for Crohn's disease diagnosis furthers Given Imaging's efforts to obtain coverage for indications beyond obscure bleeding
Given M2A Camera Pill Suspected Blood Indicator Gains 510(k) Clearance
Given Imaging will upgrade the RAPID software on its M2A camera pill computer workstation within the next 60 days for all U.S. customers with systems under warranty or service contract